These biotech companies have catalysts ahead.
MarketBeat on MSN
CRISPR Therapeutics gains after earnings as pipeline hope grows
CRISPR Therapeutics AG (NASDAQ: CRSP) stock is up more than 12% after the gene editing pioneer reported its Q4 2025 earnings ...
CRISPR-Cas9 technology has revolutionized biotechnology by providing an efficient, precise, and versatile tool for genome editing. This RNA-guided system allows scientists to target specific DNA ...
CRISPR Therapeutics’ fourth quarter was relatively disappointing. As a biotech start-up still in its infancy though, these ...
In this article, we will take a look at the Top 10 CRISPR Stocks to Buy Now. Innovation is a hallmark of the biopharmaceutical sector, which is fueled by the demand for novel therapies to address ...
CRISPR biosensors are transforming healthcare by detecting biomarkers at attomolar sensitivity, enabling real-time health monitoring through wearable patches and implantable sensors. They continuously ...
Cathie Wood's ARK Invest bought Recursion Pharmaceuticals and CRISPR Therapeutics while selling PagerDuty, Teradyne, and Salesforce on8, 2026.
CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the 10 Stocks Going Wild. Crispr Therapeutics rallied for a second day on Wednesday, adding 9.6 percent to close at $60.08 apiece, tracking the rally in ...
Crispr gene-editing technology has demonstrated its revolutionary potential in recent years: It has been used to treat rare diseases, to adapt crops to withstand the extremes of climate change, or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results